OTCMKTS:NVZMF Novozymes A/S Q1 Earnings Results & Report $68.70 0.00 (0.00%) As of 10/30/2026 Novozymes A/S missed analyst earnings expectations in its Q1 results, released April 20, 2016. The company reported EPS of $0.3710 versus the $2.43 consensus estimate. Research:Profile Earnings Announcement Details QuarterQ1Report DateApril 20, 2016TimeBefore Market Opens Novozymes A/S EPS ResultsActual EPS$0.3710Consensus EPS $2.43Beat/MissMissed by -$2.0590One Year Ago EPSN/AEPS Beat Rate2 of last 4 quartersNovozymes A/S Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsNovozymes A/S' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Novozymes A/S Q1 Earnings FAQ Did Novozymes A/S beat earnings estimates for Q1? Novozymes A/S (OTCMKTS:NVZMF) reported earnings of $0.3710 per share for Q1, missing the consensus estimate of $2.43. The report was announced on Wednesday, April 20, 2016. When is Novozymes A/S' next earnings date? Novozymes A/S' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Novozymes A/S on the company's earnings history page. Novozymes A/S Earnings HeadlinesNovonesis (Novozymes) B Class B NVZMFJuly 3, 2026 | morningstar.comMNovonesis (Novozymes A/S): Interim report Q1 2026May 5, 2026 | finanznachrichten.deThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 3 at 1:00 AM | Porter & Company (Ad)Novonesis (Novozymes A/S): Novonesis expands global footprint with acquisition of production facility in Southeast AsiaApril 8, 2026 | finanznachrichten.deNovozymes (CPSE:NSIS B): Assessing Valuation After Upward Sales Growth Guidance and Improved Q3 ResultsNovember 12, 2025 | finance.yahoo.comCould Gut Microbiome Research Shift Novozymes' Innovation Narrative in Health and Nutrition (CPSE:NSIS B)?September 8, 2025 | finance.yahoo.comSee More Novozymes A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Novozymes A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novozymes A/S and other key companies, straight to your email. Email Address About Novozymes A/SNovozymes A/S (OTCMKTS:NVZMF) was a Denmark-based biotechnology company specializing in enzymes and microorganisms for industrial, agricultural, and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use, and develop more sustainable products and processes. The company developed and marketed enzyme and microbial solutions for industries including food and beverages, household care, agriculture, bioenergy, animal health, and industrial manufacturing. Its products supported applications such as baking, brewing, detergents, textile processing, crop production, animal feed, and the conversion of biomass into renewable fuels and other materials. Novozymes served customers across global markets through research, production, and commercial operations in multiple regions. The company was established in 2000 through the separation of the enzyme business from Novo Nordisk. In 2024, Novozymes combined with Chr. Hansen Holding A/S to form Novonesis, and Novozymes ceased operating as a standalone company under its former name.View Novozymes A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another TestAlphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatUranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation Reset Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
